Posts

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus, LLC is committed to staying abreast of medical advancements and research in hair restoration to increase awareness of biomodulation as a treatment method for hair loss.

The company showcased its premiere medical laser devices to an international audience of physicians specializing in dermatology at the American Academy of Dermatology 2019 AAD Annual Meeting in Washington, D.C.

Feedback from both physicians and customers is continuously taken into consideration by the Capillus team to innovate, upgrade and improve the product line. The company is committed to bringing awareness of laser therapy as a medical treatment for androgenic alopecia, which has long been used by medical professionals in hair restoration specialties but is still relatively new to dermatology. Capillus manufactures its devices from its ISO13485:2016 certified headquarters in Miami, Florida.

Also featured at the AAD annual meeting, Capillus announced their expanded Cap+ brand line of clinical hair care products, which contains natural ingredients to cleanse, exfoliate, and moisturize hair while promoting overall scalp health.

The expanded line of Cap+ products now includes a hair health supplement and 2% minoxidil for women, in addition to its 5% minoxidil for men and other hair care products. The popular Cap+ Bundle, which includes all Cap+ products, is applied to remove build-up in hair, restore vitality to lock in moisture, reduce inflammation while lubricating hair follicles as well as repair hair damage.

Capillus also congratulates Dr. Janice Lima-Maribona, a Miami, FL Dermatologist, for winning the CapillusRx (valued at $3,499) at the AAD annual meeting. The company generated a lot of buzz and interest from physicians specialized in dermatology with hair loss patients from around the world. Capillus urges interested physicians and specialists to become a part of the Capillus Physician Network, to contact the company directly at (844)-280-4680.

In furthering their commitment to hair science and research, Capillus will also be participating in the upcoming World Congress for Hair Research taking place abroad in Barcelona on April 24th, 2019. The congress will be a comprehensive, international hair research meeting for the advancement of knowledge in hair growth.

The company’s involvement will once again be integral to staying ahead of the curve with new advancements, research, and techniques for the development of hair growth in connection with international hair loss physicians.

About Capillus, LLC

Capillus, LLC offers both prescription as well as over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss. The Capillus premier product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485). Capillus also offers additional non-prescription clinical hair products for hair and scalp health under the Cap+ and RXCap+ brand. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use.

For more information, visit: https://www.capillus.com/

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Source

 

Previous Posts

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Capillus, LLC is committed to staying abreast of medical advancements and research in hair restoration to increase awareness of biomodulation as a treatment method for hair loss.

The company showcased its premiere medical laser devices to an international audience of physicians specializing in dermatology at the American Academy of Dermatology 2019 AAD Annual Meeting in Washington, D.C.

Feedback from both physicians and customers is continuously taken into consideration by the Capillus team to innovate, upgrade and improve the product line. The company is committed to bringing awareness of laser therapy as a medical treatment for androgenic alopecia, which has long been used by medical professionals in hair restoration specialties but is still relatively new to dermatology. Capillus manufactures its devices from its ISO13485:2016 certified headquarters in Miami, Florida.

Also featured at the AAD annual meeting, Capillus announced their expanded Cap+ brand line of clinical hair care products, which contains natural ingredients to cleanse, exfoliate, and moisturize hair while promoting overall scalp health.

The expanded line of Cap+ products now includes a hair health supplement and 2% minoxidil for women, in addition to its 5% minoxidil for men and other hair care products. The popular Cap+ Bundle, which includes all Cap+ products, is applied to remove build-up in hair, restore vitality to lock in moisture, reduce inflammation while lubricating hair follicles as well as repair hair damage.

Capillus also congratulates Dr. Janice Lima-Maribona, a Miami, FL Dermatologist, for winning the CapillusRx (valued at $3,499) at the AAD annual meeting. The company generated a lot of buzz and interest from physicians specialized in dermatology with hair loss patients from around the world. Capillus urges interested physicians and specialists to become a part of the Capillus Physician Network, to contact the company directly at (844)-280-4680.

In furthering their commitment to hair science and research, Capillus will also be participating in the upcoming World Congress for Hair Research taking place abroad in Barcelona on April 24th, 2019. The congress will be a comprehensive, international hair research meeting for the advancement of knowledge in hair growth.

The company’s involvement will once again be integral to staying ahead of the curve with new advancements, research, and techniques for the development of hair growth in connection with international hair loss physicians.

About Capillus, LLC

Capillus, LLC offers both prescription as well as over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss. The Capillus premier product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485). Capillus also offers additional non-prescription clinical hair products for hair and scalp health under the Cap+ and RXCap+ brand. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use.

For more information, visit: https://www.capillus.com/

Capillus Leads Innovation & Awareness at the 77th AAD Annual Conference

Source

 

Previous Posts

Megan Wilson Public Relations Named Capillus PR Agency of Record

Megan Wilson Public Relations Named Capillus PR Agency of Record

Megan Wilson Public Relations Named Capillus PR Agency of Record

Megan Wilson Public Relations (“MWPR”) has been named PR Agency for Record by Capillus LLC, the leading producer of low-level laser therapy (“LLLT”) treatments for hair regrowth.

“Capillus® is a revolutionary company that utilizes FDA-approved methods to produce treatment options for hair loss,” said Megan Wilson, founder, and CEO of Megan Wilson Public Relations. “It is a pleasure to work with their team as the company continues to expand and innovate within the hair regrowth category.”

“Megan Wilson brings to the table over a decade of successful campaigns in the high-end beauty industry and the capabilities and expertise necessary to help Capillus® reinforce its industry-leading choice in hair regrowth treatment,” said Frances Piña Brea, Capillus® chief marketing officer.

Expressing excitement over the partnership, Carlos Piña, Capillus CEO said, “Anyone who cares about their appearance and the role it plays in their self-esteem or how others view them in society will benefit from Capillus products. Hair loss can be devastating psychologically. Our goal is to reach those for whom hair loss is a concern before it becomes an irreversible condition and working with MWPR will assist in sharing our message.”

With August being National Hair Loss Awareness month, MWPR and Capillus® kicked off their new brand awareness campaign with an appearance at Cosmoprof North America, the largest and most awarded beauty trade show in the Americas.

Later this month, Capillus® also attended the Aesthetic Everything Beauty Expo (http://www.aestheticeverythingbeautyexpo.com), hosted by celebrity Gretchen Christine Rossi (http://www.gretchenchristine.com) and attended by Dr. Doris Day (myclearskin.com) on August 10th and 11th, 2018 at the Phoenician Resort in Scottsdale, Arizona.

Up to 80% of men and 50% of women are affected by androgenetic alopecia – hair loss due to genetic factors. Capillus® is known as for their LLLT hats that can be purchased at a more affordable price than the traditional treatment cost associated with receiving LLLT at a licensed salon.

To complement the LLLT treatment, Capillus® has also created a line of clinical hair care products with minoxidil, one of the few FDA-approved treatment methods that are proven to work for hair regrowth.

About Capillus

Capillus, LLC offers prescription and over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss.

The Capillus premier product lines include low-level laser therapy (LLLT) tools that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485). Capillus also offers additional non-prescription clinical hair products for hair and scalp health. Capillus products are available directly to the public for at-home use and even to their network of physicians for office use. For more information, visit https://www.Capillus.com.

About Megan Wilson Public Relations

With almost two decades of experience producing events, as well as comprehensive and authoritative knowledge and experience managing public relations accounts in a variety of disciplines including fashion, fitness, publishing, real estate, and hospitality.

“MWPR” offers clients her vision, which is expertly brought to fruition by piecing together every element and detail to build a beautifully finished product. MWPR has been instrumental in successfully planning and executing openings, launches, and events, as well as large-scale public relations campaigns and media relations strategies for a variety of venues, personalities, and brands. Lifestyle,real estate and fashion brands including; The Salon Project by Joel Warren, The Jazz Age Lawn Party, Carol Alt, Beautique Restaurant, Dream Hotels, PIER59 STUDIOS, Ann Taylor, Gaiam, EBOOST, Corr Jensen, Vivienne Tam, Karim Rashid, Mike Ditka, Diamond Dallas Page, Colleen and Rodney Yee, and Mari Winsor.

For more information, visit http://www.meganwilsonpr.com.

Megan Wilson Public Relations Named Capillus PR Agency of Record

Source

Capillus Leaves Lasting Impression at AAD’s 76th Annual Meeting

Capillus Leaves Lasting Impression at AAD’s 76th Annual Meeting

Capillus Leaves Lasting Impression at AAD’s 76th Annual Meeting

Laser Therapy Delights Dermatologists Seeking Reputable, Non-Invasive Hair Loss Treatments for Patients

The use of low-level laser therapy (LLLT) for treating hair loss was a major topic of discussion during the American Academy of Dermatology’s 2018 AAD Annual Meeting – and rightfully so. This year’s conference was held at the San Diego Convention Center in front of more than 18,800 attendees.

One popular scientific session on LLLT sparked profound interest in Capillus, a leading provider of low-level laser therapy caps and exhibitor at the conference, among leading dermatologists worldwide.

In the session titled, “Light Based Devices: Photomodulation and Hair Growth,” Dr. Maria Hordinsky discussed the use of light therapy for patients with thinning hair. Dr. Richard Rox Anderson, Director of the Wellman Center for Photomedicine at Massachusetts General Hospital, further explained the proven science behind light-based devices as a stimulus for hair growth.

Finally, Dr. Ronda S. Farah provided a detailed overview of the FDA-cleared laser devices for hair regrowth, Capillus included. Capillus laser devices were recently selected for a study being conducted by Dr. Ronda S. Farah, a board-certified dermatologist and lector at this year’s conference.

Capillus

The subject of LLLT generated so much buzz that the Capillus booth experienced an unprecedented number of inquiries. Dermatologists from across the globe approached the exhibit wanting to know how they can incorporate Capillus laser devices into their practice and treatment plans.

At the Capillus exhibit, physicians were able to get a first-hand demonstration of how laser devices for in-office and at-home treatment work. They also learned how low-level laser therapy can be safely used in combination with any other hair restoration treatment method, including hair transplants.

The audience was introduced to Capillus’ full-line of laser therapy devices, including the revolutionary CapillusRX™, a cap containing more lasers than any other at-home LLLT device on the market. With 312 diodes, the CapillusRX™ delivers maximum coverage of the scalp and premier effectiveness in just six-minute treatment sessions. Because of its prescription strength, this new device is available only through the Capillus Physician Network.

In addition to the CapillusRX™, Capillus offers three other FDA-cleared laser caps for direct sale via http://www.capillus.com. The Capillus82™ is the most economical device with 82 laser diodes, while the Capillus202™ is on the second tier with 202 laser diodes. Finally, the CapillusPro™ is a professional-grade device with 272 laser diodes. For in-office laser treatments, Capillus also offers the Capillus OfficePro™, available to physicians and salons only.

Not only did visitors to the booth get to learn about Capillus’ top-selling laser therapy devices, they were also able to enter a drawing for a chance to win a CapillusPro™. The winner, who was randomly selected, was Dr. Ross Levy, MD, FAAD, of CareMount Medical located in Mount Kisco, New York. Capillus is also proud to welcome Dr. Levy to it’s international network of leading hair restoration surgeons and specialists.

About Capillus, LLC

Capillus, LLC offers prescription and over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss. The Capillus premier product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485). Capillus also offers additional non-prescription clinical hair products for hair and scalp health under the Cap+ and RXCap+ brand. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use.

For more information visit https://www.capillus.com.

Source

 

capillus hair loss

Capillus Helped in the Fight Against Breast Cancer

Capillus Helped in the Fight Against Breast Cancer with a Generous Donation

Capillus, LLC reinforced its commitment to breast cancer research by donating 3% of its online sales from all Capillus laser therapy caps that were purchased on Capillus.com during the month of October to the National Breast Cancer Foundation (NBCF).

Capillus is committed to helping women and men fighting breast cancer.

“On behalf of everyone at Capillus, LLC, we would like to thank all of our customers who purchased a Capillus laser therapy cap throughout the month of October,” said Capillus Chief Marketing Officer, Frances Piña-Brea. “Your purchases allowed us to make a generous contribution to help breast cancer research.”

The Capillus caps use Low Level Laser Therapy technology (LLLT), a medical treatment for hair loss that is both minimally invasive and chemical-free.

LLLT treats a myriad of issues, including androgenetic alopecia—more commonly known as male or female-pattern baldness.

Physicians sometimes recommend Capillus laser caps to patients who are seeking hair restoration post medically-induced hair loss from chemotherapy.

capillus 82Individuals are advised to consult with their doctor or physician about using Capillus for anything other than its intended purpose as it is only cleared for use by the FDA for the treatment of hereditary hair loss.

In addition, Capillus offers a complete line of hair care therapy products which use the best ingredients to gently cleanse, exfoliate, and moisturize hair to promote overall scalp health, as well as a line of Capillus’ Keratin Hair Fibers that provide a temporary quick fix for instant coverage in seconds.

Capillus currently offers three FDA-Cleared laser caps for direct sale via https://www.capillus.com. Capillus offers the Capillus82™, an economical and convenient device, which includes 82 laser diodes, the Capillus202™, a powerful yet affordable device, containing 202 laser diodes as well as the Capillus272™ Pro, a professional-grade device, with 272 laser diodes. Most recently, Capillus introduced its newest model the CapillusRX™ which contains 312 laser diodes provides maximum coverage, and is exclusively available for sale through the company’s physician network.

About Capillus, LLC 

Capillus, LLC offers prescription and over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss. The Capillus premiere product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485).

Capillus also offers additional non-prescription clinical hair products for hair and scalp health. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use.

For more information visit https://www.capillus.com.

According to their website, the NBCF’s mission is “to help and inspire hope to those affected by breast cancer through early detection, education, and support services.”

To learn more about the NBCF, please visit their website at http://www.nationalbreastcancer.org.

Source

Cappilus

Capillus Announces New 6-Minute Laser Therapy Treatment

Capillus, LLC Announces New 6-Minute Laser Therapy Treatment for Hair Regrowth

Capillus, LLC introduces 6-minute daily sessions for its laser therapy caps with continuous wave light output. All FDA-cleared models (Capillus82™, Capillus202™, Capillus272Pro™ and CapillusRX™) are now equipped with the same clinically proven technology physicians have used for years to treat thinning hair at home or on the go, but with faster treatment sessions and an updated flexible comfort fit.

The more convenient the device, the better the compliance to the treatment. Capillus strongly believes compliance means better results. As per Dr. Shelly Friedman, Scottsdale, Arizona hair restoration surgeon, “Compliance means efficacy.” Capillus strives to make its devices convenient for the treatment of hair loss. The introduction of the flexible fit design and the shorter treatment sessions does just that.

Capillus New Design of Laser Therapy Caps

Continuous wave technology means that the lasers no longer pulse during treatment as they previously did with the 30-minute treatments; instead, they remain on during the 6-minute treatment session.

This also provides other benefits such as more controlled, precise, and consistent delivery of laser energy to the scalp and an extended device lifetime to the diodes of 30%. The change does not affect FDA clearance since it does not change the indications for use.

“Capillus allocates a major portion of our income to research and development because that’s how you maintain a strong brand,” says Carlos Piña, founder and CEO of Capillus, LLC. “Each change is made with the customers comfort and convenience in mind. If it’s comfortable and easy, people are more likely to stick to the program, and compliance equals results.”

The first of their kind, these 6-minute daily treatment models transform low-level laser therapy (LLLT) into a more easy, discreet, and powerful solution for both men and women suffering with hereditary hair loss.

Not only does treatment last just a few minutes but with the new hypoallergenic polymer interior, each cap adapts to varying head shapes and sizes and hugs the scalp for a more comfortable user experience.

Available today, readers are invited to visit https://www.capillus.com to learn more about the 6-minute per day laser therapy medical devices and hair regrowth products.

About Capillus, LLC

The Miami, Florida-based company, Capillus, LLC offers prescription and over-the-counter hair regrowth products and medical devices for both men and women suffering from hair loss. The Capillus premiere product lines include low-level laser therapy (LLLT) devices that are FDA-cleared and manufactured in the US under the highest-quality certification standard for the medical device industry (ISO13485).

Capillus also offers additional non-prescription clinical hair products for hair and scalp health. Capillus products are available directly to the public for at-home use and also to their network of physicians for office use. For more information visit http://www.capillus.com.

Source

Capillus, LLC Announces New 6-Minute Laser Therapy Treatment for Hair Regrowth

Capillus82 Laser Therapy Cap

Does the NAD’s Capillus Decision Contradict the FDA

Does the NAD’s Capillus Decision Baldly Contradict the FDA?

On September 12, the NAD released its decision in its review of the Capillus82 hair growth device (Case #6107).  This case is unusual in that it addressed a challenge to a prescription-only medical device, and related closely to the FDA’s clearance of that product to be marketed.

The NAD took pains to emphasize that its decision did not contradict the device’s FDA-cleared indication for use, but did it really?

First, a little background on how the FDA treats medical devices of this kind.  Low-to-moderate-risk medical devices may be marketed without preapproval through what is known as the 510(k) clearance process.

Instead of being evaluated and approved by the FDA for safety and efficacy, the device can be “cleared” if it is “substantially equivalent” to a device that already is legally marketed.

The existing “predicate device” may itself have undergone full approval, or it too may be a 510(k) cleared device pointing to a yet earlier predicate device.

The device maker’s 510(k) submission must convince the FDA that the new device is technologically equivalent to the predicate device or is otherwise substantially equivalent in safety and effectiveness.  The intended use must be the same as that of the predicate device.

The process has been analogized to a generic drug approval predicated on chemical equivalence to an existing branded drug.

The Capillus82 is a hat with 82 laser diodes lining the inside.  Its intended use is to treat androgentic alopecia (i.e., slow hair loss) and promote hair regrowth in men and women having certain kinds of pattern baldness.

It received FDA 510(k) clearance in January 2017, with the predicate devices being the Hairmax Lasercomb and the iGrow II – no, I am not making these up – which used different form factors to apply laser light to the head, something that apparently promotes hair growth.

Clearance was applied for and granted on the basis that the Capillus82’s technology was the same as those of the Lasercomb, iGrow and other laser hair growth treatments, with minor differences that should have no impact on safety or efficacy.

capillus 82The NAD started this matter based on its own market surveillance, investigating the Capillus82’s claims that it was “clinically proven to regrow hair” and “prevent progression of hair loss,” among others.  Capillus proffered no clinical trial data on the Capillus82 to support these claims.  After all, the whole point of 510(k) clearance is to show technological equivalence to a predicate product, thus demonstrating efficacy to the FDA, without having to do trials on the new device.

But because the new device itself was not tested, NAD found Capillus’ claims unsubstantiated and recommended that they be discontinued.  In the key sentence of the decision, NAD wrote, “While the advertiser established to the FDA’s satisfaction that the Capillus82 is substantially equivalent to other devices cleared by the FDA to promote hair growth and, as a result, it can be marketed for its intended use, the cited studies are not a good fit to support the challenged claims that Capillus82 is clinically proven to regrow hair.”  Even without the establishment-claim language, the NAD added, studies on other products are “not a good fit to support the claim that Capillus laser therapy caps prevent progression of hair loss and regrow thinning hair.”

The NAD similarly recommended discontinuation of Capillus’s claim that the Capillus82 has “no known side effects,” because these claims were not supported by tests on the actual product.

Again, Capillus had relied on substantial technological equivalence to predicate products to establish Capillus82 as being safe, as well as effective, in its 510(k) submission.

So, is this a bald rejection of the FDA’s clearance process?  The NAD opened its decision by claiming deference to the regulatory authority and later wrote, “nothing in the decision prevents Capillus from making claims about its product which are consistent with its FDA clearance for indications of use, i.e., to treat androgenetic alopecia and promote hair growth in men and women with specific patterns of hair loss and skin types.”  But, to borrow a finance expression, the NAD’s explanation has some hair on it.

The claim of which NAD disapproved – “Capillus laser therapy caps prevent progression of hair loss and regrow thinning hair” – seems a straightforward statement of the product’s key benefit, consistent with its FDA-cleared indication for use.

The FDA cleared Capillus to market the Capillus82 with no disclosure of any side effects, evidently satisfied that there were none to disclose – yet the NAD considered the affirmative statement of no known side effects unsubstantiated.

Can Capillus say nothing about its product other than a dry repetition of its FDA indication language?  If the NAD is right that neither the basic benefit nor the lack of side effects is substantiated, should the product even be on the market?  It would seem that the whole premise of FDA 510(k) clearance – that clinical evidence of the safety and efficacy of Device A is transferable to substantially equivalent Device B – was rejected by the NAD.

This case serves as a heads-up to marketers of 510(k)-cleared medical devices that the NAD may regard clinical testing on the actual product as necessary to go beyond merely being permitted to market the product by making affirmative benefit claims for it, even if those benefit claims seem to be implied by the FDA’s clearance of the device.

Source

Does the NAD’s Capillus Decision Contradict the FDA

capillus

Published Clinical Study Shows Capillus Laser Therapy Safe and Effective at Treating Female Androgenetic Alopecia

Published Clinical Study Shows Capillus Laser Therapy “Safe and Effective” at Treating Female Androgenetic Alopecia

A peer-reviewed study authored by Dr. Shelly Friedman, D.O., F.A.O.C.D. and supported by Patricia Schnoor, BSBA, confirms that low-level laser therapy (LLLT) with Capillus® may play a considerable role in the treatment of androgenetic alopecia for females, given the impartial evidence illustrating favorable hair regrowth results.

The research was published in the June 2017 edition of Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery, encouraging familiarity of LLLT as a practical method of fighting hair loss at home within the greater medical community.

Dr. Friedman of the Scottsdale Institute for Cosmetic Dermatology is a board-certified hair restoration surgeon with nearly three decades of experience treating over 15,000 patients with hair loss.

Patricia Schnoor is the head of quality assurance and governmental affairs at Capillus, overseeing the assembly, testing and quality control for Capillus’ line of FDA-cleared at-home laser caps.

The study’s circulation is expected to pave access to new international markets, allowing more individuals to undergo laser therapy hair loss treatment by way of physician prescription or recommendation.

“Performing and publishing clinical research under the rigor of a prestigious journal is of critical importance for doctors prescribing under evidence based practice guidelines,” said Fernando Bermúdez, Director of International Distribution at Capillus. “Published data is also a reference for increasingly savvy consumers wanting to make an educated purchase decision before committing to a long-term treatment.”

The purpose of this randomized controlled trial was to outline the effects of photobiomodulation, or laser light, on the hair follicle and surrounding tissues in patients suffering from hair loss. The subjects consisted of 44 healthy females ages 18 to 60 years who were recruited at two separate board–approved treatment sites.

The Capillus272™ Pro was used in the study under the alias of a “handi-dome” laser device. Using the discreet dome insert with laser diodes operating at 650 nm, active participants receiving LLLT with the Capillus272 Pro™ showed a 51 percent mean increase in hair counts compared to patients who used a seemingly identical yet defunct device.

The researchers concluded that low-level laser treatment administered for 30 minutes every other day for 17 weeks is both safe and effective in treating androgenetic alopecia in healthy females between the ages of 18 to 60 with Fitzpatrick skin Types I to IV and Ludwig–Savin Baldness Scale I-2 to II-2 baldness patterns.

No side effects or adverse reactions were reported by any subject at any time during the study.

For more, view the published abstract on Dermatologic Surgery, June 2017 – Volume 43 – Edition 6.

About Capillus

Capillus proudly offers hair regrowth products and medical devices recommended by hair restoration physicians around the world for both men and women with hair loss.

Capillus’s premiere product lines include low level laser therapy (LLLT) devices that are FDA-Cleared and manufactured in the USA under the highest quality certification standard for the medical device industry (ISO13485).  Capillus272 Pro, Capillus 202, and Capillus82 are light-weight and battery-operated laser therapy caps for at-home hair loss treatment, used 30 minutes every other day and worn discreetly under a sports cap.

The Capillus272 OfficePro is for laser therapy sessions administered in salons and clinics for clients seeking introductory treatment.  Capillus laser therapy devices feature more lasers than any other FDA-Cleared clinical device on the market for non-presrciption sale. Capillus offers additional products for clinical hair therapy and scalp health as well as keratin hair fibers for temporary concealment of thin hair. Readers are invited to visit http://www.capillus.com to learn more about Capillus hair regrowth products and laser therapy medical devices.

Source

Capillus Laser Cap

Michigan Hair Surgeon Now Providing Capillus® Laser Cap to Hair Loss Patients

Michigan Hair Surgeon Now Providing Capillus® Laser Cap to Hair Loss Patients

A new, mobile low level laser therapy (LLLT) product has arrived at Accents Cosmetic Surgery to help men and women prevent the progression of hair loss.

Called the Capillus272 Pro™, this wearable laser therapy product is designed to increase the flow of blood and natural growth factors directly to hair follicles, helping patients who suffer with androgenetic alopecia develop a thicker and fuller head of hair.

“I highly recommend the Capillus272 to all of my patients who are in the market for a low-level laser light therapy device,” says Dr. Mark Berkowitz, founder of Accents Cosmetic Surgery. “It is simple to use, it has science behind it, and it’s something that I believe in and use myself.”

Capillus-LLLT-Device-Hair-Regrowth-Receives-FDA-Clearance

Capillus272 Pro™ is cleared by the FDA for the treatment of androgenetic alopecia, or hair loss, in men and women.

The laser cap has been shown to promote up to 51% increase in hair count, according to independently reviewed clinical studies available online at ClinicalTrials.gov.

Compared to other low level laser therapy options, Capillus272 Pro™ offers patients a high degree of discretion and convenience. The laser insert is placed beneath the cap of an ordinary hat or head covering, allowing patients to enjoy treatment without the worry of prying eyes. Capillus272 Pro™ is battery-operated and comes with a complimentary carrying case, allowing for consistent use around the house, at the office, and even on vacation.

“Compliance is very important for low level laser light therapy,” Dr. Berkowitz explains in a video interview. “If you aren’t going to use it, it’s never going to work. Well with a cap, it is so easy. I put it on, I drive to work with it 3 times a week or I watch TV with the cap on. If you use the Capillus®, it will work for you.”

In addition to low level laser therapy with Capillus272 Pro™, Dr. Berkowitz offers a variety of surgical and non-surgical hair restoration options for men and women who suffer with hair loss.

Dr. Berkowitz specializes in the NeoGraft hair transplant procedure, having performed hundreds of procedures totaling over 1.4 million grafts in the Michigan area.

For more information on hair restoration with Capillus272 Pro™, visit http://www.accentscosmeticsurgery.com.

Source